Evaluate the Efficacy and Safety of the ADVAGRAF®

PHASE4CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
Evidence of Liver Transplantation
Interventions
DRUG

Advagraf

"Researchers must check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~10ng/ml of study treatment. Duration of treatment The investigational product will be administered for 24 weeks. (The lowest blood levels shall be adjusted at the discretion of the researchers, taking a blood sample is carried out in the morning before administrated of Investigational Product)~Tacrolimus blood level is 3-10 ng/ml for 6 months prior to screening and during the maintenance therapy.~( ① -1day to enrollment : swich to the day before ADVAGRAF®, ② 0day to enrollment : the day swich to ADVAGRAF® )~Duration of treatment the investigational product will be administered for 24 weeks."

Trial Locations (1)

05505

Seoul Asan Medical Center, Seoul

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Asan Medical Center

OTHER

lead

Linical Korea

INDUSTRY